Route to Rheumatoid Arthritis by Macrophage-Derived Microvesicle-Coated Nanoparticles

• DOI: 10.1021/acs.nanolett.8b03439
• Publication Date: 2018-12-06T20:17:56Z
• Authors: Ruixiang Li; Yuwei He; Ying Zhu; Lixian Jiang; Shuya Zhang; Jing Qin; Qian Wu; Wentao Dai; Shun Shen; Zhiqing Pang; Jianxin Wang
• Keywords: Proteomics; Erythrocytes; Cytochalasin B; Macrophages; Polyesters; Macrophage-1 Antigen; 02 engineering and technology; Arthritis, Experimental; Tacrolimus; 3. Good health; Arthritis, Rheumatoid; Disease Models, Animal; Mice; Hyaluronan Receptors; Gene Expression Regulation; Polylactic Acid-Polyglycolic Acid Copolymer; Human Umbilical Vein Endothelial Cells; Animals; Humans; Nanoparticles; 0210 nano-technology

The targeted delivery of therapeutics to sites of rheumatoid arthritis (RA) has been a long-standing challenge. Inspired by the intrinsic inflammation-targeting capacity of macrophages, a macrophage-derived microvesicle (MMV)-coated nanoparticle (MNP) was developed for targeting RA. The MMV was efficiently produced through a novel method. Cytochalasin B (CB) was applied to relax the interaction between the cytoskeleton and membrane of macrophages, thus stimulating MMV secretion. The proteomic profile of the MMV was analyzed by iTRAQ (isobaric tags for relative and absolute quantitation). The MMV membrane proteins were similar to those of macrophages, indicating that the MMV could exhibit bioactivity similar to that of RA-targeting macrophages. A poly(lactic- co-glycolic acid) (PLGA) nanoparticle was subsequently coated with MMV, and the inflammation-mediated targeting capacity of the MNP was evaluated both in vitro and in vivo. The in vitro binding of MNP to inflamed HUVECs was significantly stronger than that of the red blood cell membrane-coated nanoparticle (RNP). Compared with bare NP and RNP, MNP showed a significantly enhanced targeting effect in vivo in a collagen-induced arthritis (CIA) mouse model. The targeting mechanism was subsequently revealed according to the proteomic analysis, indicating that Mac-1 and CD44 contributed to the outstanding targeting effect of the MNP. A model drug, tacrolimus, was encapsulated in MNP (T-RNP) and significantly suppressed the progression of RA in mice. The present study demonstrates MMV as a promising and rich material, with which to mimic macrophages, and demonstrates that MNP is an efficient biomimetic vehicle for RA targeting and treatment.